Home|Journals|Articles by Year|Audio Abstracts
 

Original Research



Comparative status of glycogen phosphorylase BB, myoglobin, and CK-MB for early diagnosis of acute myocardial infarction

Vedika Rathore, Puneet Rastogi, Y S Chandel, Neelima Singh, Roshan Kumar Mahat.




Abstract

Background: Early and correct diagnosis of acute myocardial infarction (AMI) is of utmost importance to enable the immediate and intensified treatment which consequently reduces the mortality due to AMI. Under this condition, cardiac markers are used to evaluate heart functions. Glycogen phosphorylase BB (GPBB) is new marker invented to diagnose AMI within 4 h of onset of chest pain.

Objective: The objective of the study is to compare the sensitivity and specificity of GPBB with myoglobin (MB) and creatine kinase MB (CKMB) within 4 h after the onset of chest pain.

Materials and Methods: This study includes 150 AMI patients and 100 normal healthy individuals as controls. In all the cases and controls, serum GPBB and MB were measured by enzyme-linked immunosorbent assay, whereas CK-MB was measured by diagnostic kit supplied by ERBA.

Results: The sensitivity and specificity of GPBB were greater than MB and CKMB within 4 h after the onset of chest pain.

Conclusion: GPBB was the most sensitive and specific cardiac marker compared to MB and CKMB in AMI patients during the first 4 h after the onset of chest pain. Hence, GPBB can be used for the early diagnosis of AMI.

Key words: Glycogen Phosphorylase BB; Acute Myocardial Infarction; Myoglobin; Creatine Kinase Myoglobin






Full-text options


Share this Article



Online Article Submission
• ejmanager.com
• ojshosting.net







Do you want to use OJS for your journal ?
work with an experienced partner
www.OJSHosting.net

eJManager.com
Review(er)s Central
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (https://creativecommons.org/licenses/by-nc-sa/4.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.